Press Releases

08.05.2022

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

07.28.2022

PFIZER REPORTS SECOND-QUARTER 2022 RESULTS

06.30.2022

Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™

06.29.2022

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

06.28.2022

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

06.25.2022

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

06.24.2022

Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

06.23.2022

Valneva and Pfizer Announce Closing of Equity Investment

06.23.2022

Pfizer Declares Third-Quarter 2022 Dividend

06.20.2022

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

06.17.2022

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

06.17.2022

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain